Skip to main content

Advertisement

Springer Nature Link
Log in

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Neoangiogenesis plays an important role in tumor growth and metastasis. Evaluation of new anti-angiogenic targets may broaden the armament for future therapeutic concepts. Focal adhesion kinase (FAK), expressed in endothelial and tumor cells, is essential for adhesion and mobility of adherent cells. In the current study we analyzed the anti-angiogenic properties of the FAK inhibitor TAE226 on the proliferation of blood outgrowth endothelial cell (OEC) and differentiation of endothelial progenitor cells (EPC), derived from peripheral blood CD133+ cells, tube formation and on neovascularization in a HT29 xenotransplant model. The effects of TAE226 were compared to those of the rapamycin analogue RAD001. The combination of both drugs was also studied. We showed that HT29 tumor cells and OEC were most sensitive to the action of TAE226 compared to EPC in vitro. In contrast, RAD001 affected the proliferation of both types of endothelial cells stronger than that of HT29 cells. Furthermore we could show that TAE226 inhibited tube formation in a dose dependent manner. In a HT29 subcutaneous tumor model TAE226 and RAD001 diminished MVD at commonly employed doses to a similar degree. Combination of both compounds did not show synergy in vitro or in vivo. Since TAE226 has been shown to inhibit the PI3 kinase, Akt kinase, mTor pathway, addition of RAD001 may not increase this effect. In conclusion, we have shown that treatment with TAE leads to a reduction of neoangiogenesis in vitro and in a mouse model. The effects are mediated by inhibition of angiogenesis and vasculogenic OEC and EPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

Abbreviations

BW:

Body weight

EC:

Endothelial cell

EPC:

Endothelial progenitor cell

FAK:

Focal adhesion kinase

HT29:

Colon carcinoma cell line

mTOR:

Mammalian target of rapamycin

MVD:

Microvessel density

OEC:

Outgrowth endothelial cell

RAD001:

Small molecule drug inhibiting mTOR

TAE226:

Small molecule drug inhibiting FAK

VEGF:

Vascular endothelial growth factor

References

  1. Li S, Hua ZC (2008) FAK expression regulation and therapeutic potential. Adv Cancer Res 101:45–61

    Article  CAS  PubMed  Google Scholar 

  2. Schmidmaier R, Baumann P (2008) ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem 15:978–990

    Article  CAS  PubMed  Google Scholar 

  3. Angelucci A, Bologna M (2007) Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family. Curr Pharm Des 13:2129–2145

    Article  CAS  PubMed  Google Scholar 

  4. Nakamura J, Shigematsu S, Yamauchi K, Takeda T, Yamazaki M, Kakizawa T, Hashizume K (2008) Biphasic function of focal adhesion kinase in endothelial tube formation induced by fibril-forming collagens. Biochem Biophys Res Commun 374:699–703

    Article  CAS  PubMed  Google Scholar 

  5. Das A, Yaqoob U, Mehta D, Shah VH (2009) FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol 29:562–570

    Article  CAS  PubMed  Google Scholar 

  6. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C et al (2007) Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67:10976–10983

    Article  CAS  PubMed  Google Scholar 

  7. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN (2007) A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 46:488–496

    Article  CAS  PubMed  Google Scholar 

  8. Golubovskaya VM, Virnig C, Cance WG (2008) TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 47:222–234

    Article  CAS  PubMed  Google Scholar 

  9. Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Takaoka M, Hatakeyama S, Omori O, Ohara T et al (2008) TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 20:1473–1477

    CAS  PubMed  Google Scholar 

  10. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135

    Article  CAS  PubMed  Google Scholar 

  11. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N et al (2000) In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:3106–3112

    CAS  PubMed  Google Scholar 

  12. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, Yoder MC (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104:2752–2760

    Article  CAS  PubMed  Google Scholar 

  13. Otten J, Schultze A, Schafhausen P, Otterstetter S, Dierlamm J, Bokemeyer C, Brummendorf TH, Fiedler W, Loges S (2008) Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. Br J Haematol 142:115–118

    Article  CAS  PubMed  Google Scholar 

  14. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK (2007) Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6:1357–1367

    Article  CAS  PubMed  Google Scholar 

  15. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13:4261–4270

    Article  CAS  PubMed  Google Scholar 

  16. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR (2007) RAAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67:2408–2413

    Article  CAS  PubMed  Google Scholar 

  17. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809

    Article  CAS  PubMed  Google Scholar 

  18. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK, Fiedler W (2004) Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 300:65–71

    Article  CAS  PubMed  Google Scholar 

  19. Loges S, Butzal M, Otten J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld DK, Schuch G, Fiedler W (2007) Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 357:1016–1020

    Article  CAS  PubMed  Google Scholar 

  20. Lim ST, Mikolon D, Stupack DG, Schlaepfer DD (2008) FERM control of FAK function: implications for cancer therapy. Cell Cycle 7:2306–2314

    CAS  PubMed  Google Scholar 

  21. Ding Q, Gladson CL, Wu H, Hayasaka H, Olman MA (2008) Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem 283:26839–26849

    Article  CAS  PubMed  Google Scholar 

  22. Park H, Han I, Kwon HJ, Oh ES (2005) Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells. Cancer Res 65:9899–9905

    Article  CAS  PubMed  Google Scholar 

  23. Kawahara E, Ohmori O, Nonomura K, Murakami Y, Tomioka D, Niwa S, Meyer T, Mestan J, Honda T, Hatakeyama S (2006) NVP-TAE226, a potent dual FAK/IGF-IR kinase inhibitor, prevents breast cancer metastasis in vivo. Journal of Clinical Oncology 24:18S Abstract 13163

    Article  Google Scholar 

Download references

Acknowledgements

This research was supported by Novartis Pharma AG, Basel, Switzerland. A.S. receives a bursary of the Werner Otto Foundation for Researchers in Medical Science at the University of Hamburg.

Author information

Authors and Affiliations

  1. University Medical Center Hamburg-Eppendorf, Hubertus Wald University Cancer Center Hamburg, Dept. of Oncology/Hematology with sections BMT and Pneumology, Hamburg, Germany

    Alexander Schultze, Sebastian Decker, Jasmin Otten, Gabi Vohwinkel, Gunter Schuch, Carsten Bokemeyer, Sonja Loges & Walter Fiedler

  2. Department of Clinical Chemistry, Center of Clinical Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Andrea Kristina Horst

  3. University Medical Center Hamburg-Eppendorf, Hubertus Wald University Cancer Center Hamburg, Dept. of Oncology/Hematology with sections BMT and Pneumology, Martinistrasse 52, 20246, Hamburg, Germany

    Walter Fiedler

Authors
  1. Alexander Schultze
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Sebastian Decker
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Jasmin Otten
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Andrea Kristina Horst
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Gabi Vohwinkel
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Gunter Schuch
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Carsten Bokemeyer
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Sonja Loges
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Walter Fiedler
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Walter Fiedler.

Additional information

Alexander Schultze and Sebastian Decker contributed equally

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schultze, A., Decker, S., Otten, J. et al. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Invest New Drugs 28, 825–833 (2010). https://doi.org/10.1007/s10637-009-9326-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9326-5

Keywords